SEARCH

SEARCH BY CITATION

References

  • Angoa-Perez M., Kane M. J., Francescutti D. M., Sykes K. E., Shah M. M., Mohammed A. M., Thomas D. M. and Kuhn D. M. (2012) Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J. Neurochem. 120, 10971107.
  • Baumann M. H., Ayestas M. A. Jr, Partilla J. S., Sink J. R., Shulgin A. T., Daley P. F., Brandt S. D., Rothman R. B., Ruoho A. E. and Cozzi N. V. (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37, 11921203.
  • Borek H. A. and Holstege C. P. (2012) Hyperthermia and multiorgan failure after abuse of ‘bath salts’ containing 3,4-methylenedioxypyrovalerone. Ann. Emerg. Med. 60, 103105.
  • Brogden R. N., Heel R. C., Speight T. M. and Avery G. S. (1979) Nomifensine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 18, 124.
  • Brunt T. M., Poortman A., Niesink R. J. and van den Brink W. (2011) Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharmacol. 25, 15431547.
  • Cadet J. L., Krasnova I. N., Jayanthi S. and Lyles J. (2007) Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox. Res. 11, 183202.
  • Caldwell J. (1976) The metabolism of amphetamines in mammals. Drug Metab. Rev. 5, 219280.
  • Cozzi N. V. and Foley K. F. (2003) Methcathinone is a substrate for the serotonin uptake transporter. Pharmacol. Toxicol. 93, 219225.
  • Cozzi N. V., Sievert M. K., Shulgin A. T., Jacob P. III and Ruoho A. E. (1999) Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur. J. Pharmacol. 381, 6369.
  • Escubedo E., Abad S., Torres I., Camarasa J. and Pubill D. (2011) Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity. Neurochem. Int. 58, 92101.
  • Fass J. A., Fass A. D. and Garcia A. S. (2012) Synthetic cathinones (bath salts): legal status and patterns of abuse. Ann. Pharmacother. 46, 436441.
  • Feyissa A. M. and Kelly J. P. (2008) A review of the neuropharmacological properties of khat. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 11471166.
  • Fleckenstein A. E., Gibb J. W. and Hanson G. R. (2000) Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol. 406, 113.
  • Fleckenstein A. E., Volz T. J., Riddle E. L., Gibb J. W. and Hanson G. R. (2007) New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 47, 681698.
  • Fumagalli F., Gainetdinov R. R., Valenzano K. J. and Caron M. G. (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci. 18, 48614869.
  • Greene S. L., Kerr F. and Braitberg G. (2008) Review article: amphetamines and related drugs of abuse. Emerg. Med. Australas. 20, 391402.
  • Gygi M. P., Gibb J. W. and Hanson G. R. (1996) Methcathinone: an initial study of its effects on monoaminergic systems. J. Pharmacol. Exp. Ther. 276, 10661072.
  • Gygi M. P., Fleckenstein A. E., Gibb J. W. and Hanson G. R. (1997) Role of endogenous dopamine in the neurochemical deficits induced by methcathinone. J. Pharmacol. Exp. Ther. 283, 13501355.
  • Hadlock G. C., Webb K. M., McFadden L. M. et al. (2011) 4-Methylmethcathinone(mephedrone): neuropharmacological effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther. 339, 530536.
  • Kalix P. and Glennon R. A. (1986) Further evidence for an amphetamine-like mechanism of action of the alkaloid cathinone. Biochem. Pharmacol. 35, 30153019.
  • Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F. and Yoshitake T. (2011) Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br. J. Pharmacol. 164, 19491958.
  • Kelly J. P. (2011) Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test. Anal. 3, 439453.
  • Kiyatkin E. A. and Sharma H. S. (2009) Acute methamphetamine intoxication: brain hyperthermia, blood-brain barrier, brain edema, and morphological cell abnormalities. Int. Rev. Neurobiol. 88, 65100.
  • Kuhn D. M. and Billingsley M. L. (1987) Tyrosine hydroxylase: purification from PC -12 cells, characterization, and production of antibodies. Neurochem. Int. 11, 463475.
  • Kuhn D. M., Francescutti-Verbeem D. M. and Thomas D. M. (2008) Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicity. Ann. N. Y. Acad. Sci. 1139, 118126.
  • Kuwayama K., Tsujikawa K., Miyaguchi H., Kanamori T., Iwata Y. T. and Inoue H. (2012) Interaction of 3,4-methylenedioxymethamphetamine and methamphetamine during metabolism by in vitro human metabolic enzymes and in rats. J. Forensic Sci. 57, 10081013.
  • Lopez-Arnau R., Martinez-Clemente J., Pubill D., Escubedo E. and Camarasa J. (2012) Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br. J. Pharmacol. 167, 407420.
  • Marek G. J., Vosmer G. and Seiden L. S. (1990) Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res. 513, 274279.
  • Martinez-Clemente J., Escubedo E., Pubill D. and Camarasa J. (2012) Interaction of mephedrone with dopamine and serotonin targets in rats. Eur. Neuropsychopharmacol. 22, 231236.
  • McCann U. D., Wong D. F., Yokoi F., Villemagne V., Dannals R. F. and Ricaurte G. A. (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J. Neurosci. 18, 84178422.
  • McErath K. and O'Neill C. (2011) Experiences with mephedrone pre- and post-legistrative controls: perceptions of safety and sources of supply. Int. J. Drug Policy 22, 120127.
  • Meyer M. R. and Maurer H. H. (2010) Metabolism of designer drugs of abuse: an updated review. Curr. Drug Metab. 11, 468482.
  • Morris K. (2010) UK places generic ban on mephedrone drug family. Lancet 375, 13331334.
  • Nagai F., Nonaka R. and Satoh Hisashi Kamimura K. (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol. 559, 132137.
  • Poth L. S., O'Connell B. P., McDermott J. L. and Dluzen D. E. (2012) Nomifensine alters sex differences in striatal dopamine function. Synapse 66, 686693.
  • Prosser J. M. and Nelson L. S. (2012) The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol. 8, 3342.
  • Pu C., Fisher J. E., Cappon G. D. and Vorhees C. V. (1994) The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum. Brain Res. 649, 217224.
  • Rockhold R. W., Carlton F. B. Jr, Corkern R., Derouen L., Bennett J. G. and Hume A. S. (1997) Methcathinone intoxication in the rat: abrogation by dextrorphan. Ann. Emerg. Med. 29, 383391.
  • Rothman R. B., Vu N., Partilla J. S., Roth B. L., Hufeisen S. J., Compton-Toth B. A., Birkes J., Young R. and Glennon R. A. (2003) In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J. Pharmacol. Exp. Ther. 307, 138145.
  • Schifano F., Albanese A., Fergus S. et al. (2011) Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues. Psychopharmacology 214, 593602.
  • Schmidt C. J. and Gibb J. W. (1985) Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: effects of amfonelic acid. Eur. J. Pharmacol. 109, 7380.
  • Schmidt C. J., Ritter J. K., Sonsalla P. K., Hanson G. R. and Gibb J. W. (1985) Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther. 233, 539544.
  • Sogawa C., Sogawa N., Ohyama K., Kikura-Hanajiri R., Goda Y., Sora I. and Kitayama S. (2011) Methylone and monoamine transporters: correlation with toxicity. Curr. Neuropharmacol. 9, 5862.
  • Sparago M., Wlos J., Yuan J., Hatzidimitriou G., Tolliver J., Dal Cason T. A. Katz J. and Ricaurte G. (1996) Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse. J. Pharmacol. Exp. Ther. 279, 10431052.
  • Sulzer D. (2011) How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 69, 628649.
  • Tanner-Smith E. E. (2006) Pharmacological content of tablets sold as ‘ecstasy’: results from an online testing service. Drug Alcohol Depend. 83, 247254.
  • Teng S. F., Wu S. C., Liu C., Li J. H. and Chien C. S. (2006) Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005. Forensic Sci. Int. 161, 202208.
  • Thomas D. M., Walker P. D., Benjamins J. A., Geddes T. J. and Kuhn D. M. (2004) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J. Pharmacol. Exp. Ther. 311, 17.
  • Thomas D. M., Francescutti-Verbeem D. M. and Kuhn D. M. (2008) The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J. Neurochem. 105, 605616.
  • Thomas D. M., Francescutti-Verbeem D. M. and Kuhn D. M. (2009) Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity. J. Neurochem. 109, 17451755.
  • Thomas D. M., Angoa Perez M., Francescutti-Verbeem D. M., Shah M. M. and Kuhn D. M. (2010) The role of endogenous serotonin in methamphetamine-induced neurotoxicity to dopamine nerve endings of the striatum. J. Neurochem. 115, 595605.
  • Torrance H. and Cooper G. (2010) The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci. Int. 202, e62e63.
  • Winstock A., Mitcheson L., Ramsey J., Davies S., Puchnarewicz M. and Marsden J. (2011a) Mephedrone: use, subjective effects and health risks. Addiction 106, 19911996.
  • Winstock A. R., Mitcheson L. R., Deluca P., Davey Z., Corazza O. and Schifano F. (2011b) Mephedrone, new kid for the chop? Addiction 106, 154161.
  • Yamamoto B. K. and Bankson M. G. (2005) Amphetamine neurotoxicity: cause and consequence of oxidative stress. Crit. Rev. Neurobiol. 17, 87117.
  • Yamamoto B. K., Nash J. F. and Gudelsky G. A. (1995) Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther. 273, 10631070.